Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC

"Conversion therapy stage:~TP regimen: Albumin-bound paclitaxel+Platinum (Cisplatin or Carboplatin) Albumin-bound paclitaxel: 100 mg/m² by IV infusion, D1/D8, every 3 weeks (Q3W) Platinum: Cisplatin 75 mg/m² by IV infusion or Carboplatin AUC=5 mg/mL/min Q3W Cetuximab: The initial dose is 400 mg/m² by IV infusion for 1 week. Subsequently followed by 250 mg/m² IV infusion, D1/D8, Q3W.~Tislelizumab: 200 mg by IV infusion, Q3W. 3 weeks/cycle, 3 cycles in total.~Patients who have completed conversion therapy undergo efficacy evaluation.~Radical therapy stage:~Evaluated as operable: Undergo surgery, followed by one cycle of adjuvant chemotherapy according to the preoperative regimen.~Evaluated as inoperable: Receive radical radiotherapy.~Maintenance therapy stage:~Tislelizumab for 1 year or until disease progression, intolerable toxicity, or patient refusal to continue treatment."